Natco Pharma Upgraded to Hold as Technicals Improve Despite Recent Earnings Setback

Technical Trends Shift to Bullish Momentum

The primary catalyst for the rating upgrade is the marked improvement in Natco Pharma’s technical profile. The technical grade has shifted from sideways to bullish, signalling stronger market momentum. Key indicators underpinning this shift include a bullish Moving Average Convergence Divergence (MACD) on the weekly chart and a mildly bullish stance on the monthly timeframe. The Relative Strength Index (RSI) presents a nuanced picture, with weekly readings bearish but monthly readings bullish, suggesting short-term caution but longer-term strength.

Bollinger Bands confirm this positive momentum, showing bullish signals on both weekly and monthly charts. Daily moving averages have turned bullish, reinforcing the upward trend in the near term. The Know Sure Thing (KST) indicator is bullish on a weekly basis but bearish monthly, indicating some divergence in momentum across timeframes. Dow Theory assessments are mildly bullish on both weekly and monthly scales, while On-Balance Volume (OBV) is neutral weekly but bullish monthly, reflecting increasing buying interest over the longer term.

These technical improvements have contributed significantly to the stock’s recent price appreciation, with the current price at ₹1,036.95, up 3.47% on the day, and trading close to its 52-week high of ₹1,059.60. The stock’s recent trading range between ₹1,014.00 and ₹1,051.20 further supports the bullish technical outlook.

Valuation Remains Attractive Amidst Market Volatility

Natco Pharma’s valuation metrics have also supported the upgrade. The company boasts a Price to Book Value (P/B) ratio of 2.1, which is considered fair and attractive relative to its pharmaceutical peers and historical averages. This valuation is particularly notable given the company’s strong Return on Equity (ROE) of 17.8%, indicating efficient capital utilisation and profitability relative to shareholder equity.

Despite a recent quarter marked by negative financial performance, the stock’s valuation remains compelling. The market capitalisation grade stands at 3, reflecting a mid-tier market cap status that balances growth potential with stability. The stock’s performance relative to the broader market has been impressive, with a 1-year return of 27.76% compared to the Sensex’s 5.52% gain, and a 3-year return of 86.92% versus the Sensex’s 32.25%. This outperformance underscores investor confidence in the company’s long-term prospects despite short-term earnings pressure.

Financial Trend: Mixed Signals but Underlying Strength

While the recent quarter (Q3 FY25-26) saw a decline in key financial metrics, the company’s overall financial health remains robust. Net sales fell sharply by 41.0% to ₹647.30 crores compared to the previous four-quarter average, while Profit Before Tax (PBT) excluding other income dropped 71.6% to ₹103.00 crores. Net profit (PAT) also declined by 60.6% to ₹151.50 crores. These figures highlight near-term challenges, possibly linked to market or operational disruptions.

However, the company’s low debt-to-equity ratio, averaging zero, provides a strong balance sheet foundation, reducing financial risk. High management efficiency is evident in the ROE of 16.25% for the quarter, signalling effective use of equity capital despite earnings pressure. Institutional investors hold a significant 20.55% stake, which increased by 0.59% over the previous quarter, reflecting confidence from sophisticated market participants who typically conduct rigorous fundamental analysis.

Quality Assessment: Stable Fundamentals Amid Earnings Volatility

Natco Pharma’s quality rating remains steady, supported by strong management efficiency and prudent capital structure. The company’s ability to maintain a high ROE and zero debt levels indicates disciplined financial management. However, the recent earnings decline tempers the quality outlook, suggesting the need for cautious monitoring of operational performance in upcoming quarters.

The company’s Mojo Score stands at 64.0, with a Mojo Grade upgraded to Hold from Sell as of 10 March 2026. This reflects a balanced view of the company’s prospects, acknowledging both the technical and valuation improvements and the recent financial setbacks. The stock’s market cap grade of 3 further supports a moderate risk profile suitable for investors seeking exposure to pharmaceuticals with a cautious stance.

Market Performance and Comparative Returns

Natco Pharma’s stock has demonstrated strong relative performance across multiple time horizons. Over the past week, the stock returned 8.42%, significantly outperforming the Sensex’s decline of 2.53%. Over one month, the stock surged 22.47%, while the Sensex fell 7.20%. Year-to-date returns stand at 14.76% versus the Sensex’s negative 8.23%. Over one year, the stock’s 27.76% gain dwarfs the Sensex’s 5.52% rise.

Longer-term returns also favour Natco Pharma, with a 3-year return of 86.92% compared to the Sensex’s 32.25%. However, over five and ten years, the stock’s returns of 25.59% and 113.36% respectively lag behind the Sensex’s 52.51% and 217.61%, indicating some moderation in very long-term growth relative to the broader market.

Conclusion: Hold Rating Reflects Balanced Outlook

The upgrade of Natco Pharma Ltd. to a Hold rating reflects a nuanced assessment of the company’s current position. The technical indicators have improved significantly, signalling renewed investor interest and positive price momentum. Valuation metrics remain attractive, supported by a strong ROE and reasonable price-to-book ratio. Financially, the company faces short-term challenges with declining quarterly sales and profits, but its strong balance sheet and management efficiency provide a cushion.

Institutional investor confidence and market-beating returns over recent periods further support the Hold rating. Investors should monitor upcoming quarterly results closely to assess whether the company can stabilise earnings and sustain its technical momentum. For now, the Hold rating suggests a cautious but optimistic stance, recognising both the risks and opportunities inherent in Natco Pharma’s current profile.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today